Holen Sie sich die Stockscreener-App
4.91
4.10%
-0.21
Handel nachbörslich:
4.91
Schlusskurs vom Vortag:
$5.12
Offen:
$5.1
24-Stunden-Volumen:
62,765
Relative Volume:
0.17
Marktkapitalisierung:
$40.15M
Einnahmen:
$120.77M
Nettoeinkommen (Verlust:
$32.69M
KGV:
1.6846
EPS:
2.9146
Netto-Cashflow:
$-50.94M
1W Leistung:
-24.46%
1M Leistung:
+17.46%
6M Leistung:
-59.25%
1J Leistung:
-27.15%
1-Tages-Spanne:
$4.82
$5.26
1-Wochen-Bereich:
$4.82
$6.45
52-Wochen-Spanne:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Firmenname
Atara Biotherapeutics Inc
Sektor
Branche
Telefon
805-623-4211
Adresse
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ALNY, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.91 | 40.15M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
454.00 | 115.33B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
732.87 | 77.48B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
312.17 | 41.40B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
663.93 | 41.09B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
275.28 | 30.56B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-11-09 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-11-09 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-11-09 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-20 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-07-13 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-07-13 | Herabstufung | Stifel | Buy → Hold |
| 2022-05-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-05-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-12-09 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-11-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-30 | Eingeleitet | Evercore ISI | Outperform |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-23 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-11-08 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-09-27 | Herabstufung | Goldman | Neutral → Sell |
| 2019-09-16 | Herabstufung | Jefferies | Buy → Hold |
| 2019-06-04 | Hochstufung | Citigroup | Sell → Neutral |
| 2019-05-30 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-23 | Eingeleitet | Stifel | Buy |
| 2019-01-23 | Eingeleitet | Mizuho | Buy |
| 2018-04-10 | Eingeleitet | JP Morgan | Overweight |
| 2018-03-16 | Eingeleitet | Guggenheim | Neutral |
| 2018-03-05 | Bestätigt | Jefferies | Buy |
| 2018-02-28 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-02-15 | Herabstufung | Citigroup | Neutral → Sell |
| 2018-01-03 | Hochstufung | Citigroup | Sell → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
Alle ansehen
Atara Biotherapeutics Inc Aktie (ATRA) Neueste Nachrichten
Panacea entities boost Atara (ATRA) stake via 259,163-share warrant exercise - Stock Titan
What are analysts price targets for Atara Biotherapeutics Inc2026 Valuation Update & Breakout Confirmation Alerts - baoquankhu1.vn
[S-3] Atara Biotherapeutics, Inc. Shelf Registration Statement | ATRA SEC FilingForm S-3 - Stock Titan
Market Recap: Will Atara Biotherapeutics Inc benefit from AI trendsEarnings Trend Report & Weekly Momentum Stock Picks - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com Nigeria
Atara Biotherapeutics, Inc. 2025 Annual Report: Strategic Alternatives, Business Overview, and Risk Factors - Minichart
Form 424B5 Atara Biotherapeutics Inc For: 16 March By Investing.com - Investing.com Australia
Atara Biotherapeutics: Q4 Loss & Annual Profit 2025 Financial ResultsNews and Statistics - IndexBox
Atara Biotherapeutics: Q4 Earnings Snapshot - kens5.com
Atara Biotherapeutics (NASDAQ: ATRA) registers $11.1M ATM offering via TD Cowen - Stock Titan
Atara Biotherapeutics (ATRA) bets on tab-cel as layoffs, FDA pushback mount - Stock Titan
Atara (NASDAQ: ATRA) turns 2025 profit and targets cash runway into 2026 - Stock Titan
Atara Biotherapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Operational Progress - The Joplin Globe
Atara Biotherapeutics: Fourth Quarter Earnings Overview - Bitget
Prasad’s rule by fiat spilled into accelerated approvals in hematology and oncology Atara Bio’s Cokey Nguyen: Normally, FDA wants to help us succeed. Now, “we’re getting new guidance at the last minute and it’s not helping.” - The Cancer Letter
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
FDA to hold Type A meeting on Atara Biotherapeutics (ATRA) EBVALLO tab-cel BLA - Stock Titan
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Yahoo Finance
Atara (ATRA) CEO granted 81,100 RSUs, now holds 143,078 shares - Stock Titan
Atara Biotherapeutics (ATRA) awards 20,300 RSUs to Chief Accounting Officer - Stock Titan
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Sahm
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus - TechStock²
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Aug Closing: Can Atara Biotherapeutics Inc sustain earnings growth2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Chart Watch: Is Atara Biotherapeutics Inc being accumulated by smart moneyJobs Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Why Atara Biotherapeutics Inc. stock is popular among millennials2025 Trading Recap & Verified Entry Point Signals - Naître et grandir
Aug Momentum: Is Atara Biotherapeutics Inc forming a breakout patternJuly 2025 Catalysts & Short-Term Swing Trade Alerts - baoquankhu1.vn
Profit Review: Will Atara Biotherapeutics Inc benefit from green energy policiesEarnings Recap Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection - Stocktwits
Atara Biotherapeutics (ATRA) CAO sells 2,104 shares to cover taxes - Stock Titan
Atara Biotherapeutics provides regulatory update on tabelecleucel - marketscreener.com
Atara, Pierre Fabre seek FDA meeting on EBVALLO - TipRanks
Atara Biotherapeutics (ATRA) and Partner Seek FDA Meeting for Ta - GuruFocus
Atara Biotherapeutics partner seeks Type A FDA meeting on tabelecleucel following CRL - TradingView
Atara Biotherapeutics (ATRA) requests FDA Type A meeting on EBVALLO™ - Stock Titan
Atara Biotherapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Insider sale: ATRA (NASDAQ: ATRA) 7,788 RSU shares settled 03/01/2026 - Stock Titan
ATRA (NASDAQ) insider resale notice: 4,759 RSU shares reported - Stock Titan
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ATRA Should I Buy - Intellectia AI
Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Market Overview: Can Atara Biotherapeutics Inc stock double in the next yearStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Atara extends $9M milestone payment deadline to 2028 By Investing.com - Investing.com Australia
Finanzdaten der Atara Biotherapeutics Inc-Aktie (ATRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atara Biotherapeutics Inc-Aktie (ATRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Mar 02 '26 |
Sale |
5.08 |
2,104 |
10,691 |
31,750 |
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):